Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of BMS-708163 administered as single and multiple doses in Chinese subjects

Key facts

Study ID

NCT01079819

Run by

Bristol-Myers Squibb

People needed

32

Starts

2010-04-01

Expected to finish

2010-12-01

Last updated by the study team

2011-02-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Healthy male subjects 18-45 yrs old and 65 yrs or older inclusive and postmenopausal female 65 yrs or older

You may not qualify if…

• Women of childbearing potential
• Gastrointestinal disorders
• Bleeding disorders
• Peptic ulcer disease
• Abnormal ECG
• Abnormal Clinical laboratory tests
• Abnormal Thyroid
• Congestive heart failure
• Cholecystectomy
• Asthma
• Hypertension
• Inability to tolerate oral medication
• Inability to be venipunctured and/or tolerate venous access

Where it is running

• West Coast Clinical Trials, Llc — Cypress, California, United States
• California Clinical Trials Medical Group — Glendale, California, United States
• Iberica Clinical Research Center — Eatontown, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.